If you’re a heart patient, I’m betting that you’re already taking one of the cholesterol-lowering drugs called statins. That’s because these drugs – with brand names like Lipitor, Crestor, Zocor or any of their generic forms – are routinely prescribed to those diagnosed with cardiovascular disease. Many studies (largely funded by the drug companies that make statins) suggest that, for heart attack survivors, these drugs may help to significantly lower our risk of having another cardiac event. It’s what doctors call “secondary prevention”.
Some studies further suggest that statins are also useful for those who’ve never had heart disease, but who do have high LDL (or “bad”) cholesterol – what’s called “primary prevention”. But recently, statins hit the front page of The New York Times with a big fat *splat* when new clinical practice guidelines for treating/preventing heart disease were released by the American Heart Association and the American College of Cardiology (both heart organizations that are coincidentally largely funded by drug companies, too). The guidelines essentially said: from now on, forget about your LDL numbers. It’s all about your risk factors now.